marked.bio

Company

D3 Bio

3 active trials that select patients by a biomarker on marked.bio, across 3 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

pembrolizumab 1cetuximab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

3 of 3 trials shown

  1. A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

    Recruiting Phase 1/2 D3 Bio Started 2023Primary completion 2028-08 NCT05886920

    D3S-002D3S-001

    Note: EGFR mutations include but are not limited to EGFR Exon19 Deletions, Exon21 p.L858R, Exon21 p.L861Q, Exon18 p.G719X, Exon20 p.S768I, Exon20 Insertions, Exon20 p.T790M.

    EGFR exon 19 deletion / L858REGFR exon 20 insertionKRAS G12CAdvanced Solid Tumors With MAPK Pathway Mutations

  2. A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

    Recruiting Phase 1/2 D3 Bio Started 2022Primary completion 2027-04 NCT05410145

    D3S-001pembrolizumabcisplatincarboplatinpemetrexedcetuximab

    Subject must have documented KRAS p.G12C mutation identified within the last 5 years by a local test on tumor tissue or blood.

    KRAS G12CKRAS P.G12C

  3. A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.

    Recruiting Phase 1 D3 Bio Started 2026Primary completion 2028-01 NCT07456046

    D3S-003

    Subjects must have documented presence of KRAS p.G12D mutation by a local test identified through tumor tissue or blood collected within the la…

    KRAS G12DKRAS P.G12D